ArticleFrontiers in cellular and infection microbiology2013
Engineering production of functional scFv antibody in E. coli by co-expressing the molecule chaperone Skp.
Article in Frontiers in cellular and infection microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 57 citations in OpenAlex.
- A Paradigm Shift in Snakebite Envenoming Therapy: From Conventional Antivenoms to Rationally Designed, Broadly Neutralizing Combination Therapies.ACS pharmacology & translational science · 2026Review
- The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy.Frontiers in bioengineering and biotechnology · 2026Review
- A biosensor toolbox for monitoring recombinant protein production inFrontiers in bioengineering and biotechnology · 2026Article
- Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence.International journal of biological sciences · 2025Review
- Review
- BMFPs, a versatile therapeutic tool for redirecting a preexisting Epstein-Barr virus antibody response toward defined target cells.Science advances · 2022Article
- Effects of variable domain orientation on anti-HER2 single-chain variable fragment antibody expressed in the Escherichia coli cytoplasm.Biotechnology progress · 2021Article
- Evolution ofInternational journal of molecular sciences · 2020Review
- Crystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer's disease.The Journal of biological chemistry · 2020Article
- Solubility, Stability, and Avidity of Recombinant Antibody Fragments Expressed in Microorganisms.Frontiers in microbiology · 2020Review
- Design and Production of Bispecific Antibodies.Antibodies (Basel, Switzerland) · 2019Review
- Constructive approach for synthesis of a functional IgG using a reconstituted cell-free protein synthesis system.Scientific reports · 2019Article
- Tuning recombinant protein expression to match secretion capacity.Microbial cell factories · 2018Article
- Article
- Screening of a ScFv Antibody With High Affinity for Application in Human IFN-γ Immunoassay.Frontiers in microbiology · 2018Article
- An overview on molecular chaperones enhancing solubility of expressed recombinant proteins with correct folding.International journal of biological macromolecules · 2017Review
- Antibody Engineering for Pursuing a Healthier Future.Frontiers in microbiology · 2017Review
- The pathogenesis, detection, and prevention of Vibrio parahaemolyticus.Frontiers in microbiology · 2015Article
- Folding LacZ in the periplasm of Escherichia coli.Journal of bacteriology · 2014Article
- Development of a functional antibody by using a green fluorescent protein frame as the template.Applied and environmental microbiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-chain variable fragment (scFv) is a class of engineered antibodies generated by the fusion of the heavy (VH) and light chains (VL) of immunoglobulins through a short polypeptide linker. ScFv play a critical role in therapy and diagnosis of human diseases, and may in fact also be developed into a potential diagnostic and/or therapeutic agent. However, the fact that current scFv antibodies have poor stability, low solubility, and affinity, seriously limits their diagnostic and clinical implication. Here we have developed four different expression vectors, and evaluated their abilities to express a soluble scFv protein. The solubility and binding activity of the purified proteins were determined using both SDS-PAGE and ELISA. Amongst the four purified proteins, the Skp co-expressed scFv showed the highest solubility, and the binding activity to antigen TLH was 3-4 fold higher than the other three purified scFv. In fact, this scFv is specific for TLH and does not cross-react with other TLH-associated proteins and could be used to detect TLH directly in real samples. These results suggest that the pACYC-Duet-skp co-expression vector might be a useful tool for the production of soluble and functional scFv antibody.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.